Krystal Biotech (NASDAQ:KRYS) Trading Up 7% Following Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS) shares were up 7% on Friday after TD Cowen raised their price target on the stock from $202.00 to $306.00. TD Cowen currently has a buy rating on the stock. Krystal Biotech traded as high as $261.54 and last traded at $266.3250. Approximately 38,914 shares changed hands during trading, a decline of 86% from the average daily volume of 270,878 shares. The stock had previously closed at $248.91.

Several other research firms also recently issued reports on KRYS. Citigroup upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $198.00 to $309.00 in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. HC Wainwright reissued a “buy” rating and issued a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday. Finally, Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $260.50.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.70% of the company’s stock.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC raised its stake in Krystal Biotech by 4.4% in the third quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after buying an additional 117,777 shares in the last quarter. State Street Corp raised its position in shares of Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Braidwell LP lifted its stake in Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

The company’s 50 day simple moving average is $227.55 and its 200 day simple moving average is $182.63. The company has a market capitalization of $7.58 billion, a PE ratio of 39.19 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The business had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. On average, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.